Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions?

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...
pharmaphorum

Change at the top of Recursion as co-founder leaves CEO role

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Investopedia

What Are Hybrid Funds? Insight Into Multi-Asset Class Investments

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...